HomeCompareVRAR vs MRK

VRAR vs MRK: Dividend Comparison 2026

VRAR yields 377.57% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRAR wins by $7521.25M in total portfolio value
10 years
VRAR
VRAR
● Live price
377.57%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7521.31M
Annual income
$4,944,975,138.14
Full VRAR calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VRAR vs MRK

📍 VRAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRARMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRAR + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRAR pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRAR
Annual income on $10K today (after 15% tax)
$32,093.64/yr
After 10yr DRIP, annual income (after tax)
$4,203,228,867.42/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, VRAR beats the other by $4,203,220,539.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRAR + MRK for your $10,000?

VRAR: 50%MRK: 50%
100% MRK50/50100% VRAR
Portfolio after 10yr
$3760.68M
Annual income
$2,472,492,468.14/yr
Blended yield
65.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VRAR
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$12.00
+2165.4% upside vs current
Range: $12.00 — $12.00
Altman Z
-5.6
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRAR buys
0
MRK buys
0
No recent congressional trades found for VRAR or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRARMRK
Forward yield377.57%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$7521.31M$56.8K
Annual income after 10y$4,944,975,138.14$9,798.13
Total dividends collected$7280.40M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$12.00$128.54

Year-by-year: VRAR vs MRK ($10,000, DRIP)

YearVRAR PortfolioVRAR Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$48,457$37,757.22$11,206$366.19+$37.3KVRAR
2$222,841$170,991.59$12,650$502.35+$210.2KVRAR
3$973,338$734,898.24$14,407$694.19+$958.9KVRAR
4$4,041,410$2,999,938.35$16,585$967.82+$4.02MVRAR
5$15,965,510$11,641,201.73$19,342$1,363.89+$15.95MVRAR
6$60,062,851$42,979,755.42$22,913$1,947.19+$60.04MVRAR
7$215,380,765$151,113,513.41$27,662$2,823.89+$215.35MVRAR
8$736,888,664$506,431,246.00$34,159$4,173.35+$736.85MVRAR
9$2,407,787,131$1,619,316,260.18$43,337$6,308.80+$2407.74MVRAR
10$7,521,307,368$4,944,975,138.14$56,776$9,798.13+$7521.25MVRAR

VRAR vs MRK: Complete Analysis 2026

VRARStock

The Glimpse Group, Inc., a virtual reality (VR) and augmented reality (AR) platform company, provides enterprise-focused software, services, and solutions in the United States. It offers QReal, a software that creates and distributes photorealistic 3D and AR content; Adept XR Learning, which provides higher education learning and corporate VR training solutions; PostReality, a cloud-based software as a service solution that enables users to create AR presentations; and XR Platform, a cloud-based, scalable and secure backend infrastructure, including proprietary cloud image recognition technology, online storage, creation and management of subscription plans, and invoicing and payments designed for VR/AR companies. The company also provides D6 VR, a VR-based, analysis, presentation, and education software platform; Immersive Health Group, a digital health platform that leverages VR/AR technology to simplify and streamline complex healthcare challenges in scale; Foretell Reality, an enterprise-grade and easy-to-use solution for meeting others in VR; and Early Adopter, which offers immersive VR and AR EdTech solutions for K-12 schools and pediatric hospital programs. In addition, it offers AUGGD that provides AR software and services primarily for the architecture, engineering, and construction industries; Glimpse Turkey for developing and creating web optimized 3D models, primarily for QReal; and custom specialized AR applications, and white label solutions and services. Further, the company provides Pagoni VR that offers VR video broadcasting solutions, which consists of Chimera that enables real-time communications between a presenter, and local and remote attendees in VR to universities, enterprise, entertainment venues, sports venues, and houses of worship. The company was incorporated in 2016 and is headquartered in New York, New York.

Full VRAR Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VRAR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRAR vs SCHDVRAR vs JEPIVRAR vs OVRAR vs KOVRAR vs MAINVRAR vs JNJVRAR vs ABBVVRAR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.